 | Up a level |
Number of items: 1.
Clarke, Caroline S, Hunter, Rachael M, Gabrio, Andrea, Brawley, Christopher D, Ingleby, Fiona C, Dearnaley, David P, Matheson, David, Attard, Gerhardt, Rush, Hannah L, Jones, Rob J 
ORCID: 0000-0001-5608-001X et al (show 12 more authors)
(2022)
Cost-utility analysis of adding abiraterone acetate plus prednisone/prednisolone to long-term hormone therapy in newly diagnosed advanced prostate cancer in England: Lifetime decision model based on STAMPEDE trial data.
PloS one, 17 (6).
e0269192-e0269192.